Skip to content
lifestyle.the-newshub.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AC Immune SA
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
August 11, 2026
AC Immune First Half 2026 Financial and Corporate Update
August 5, 2026
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
July 7, 2026
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease
June 30, 2026
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
June 11, 2026
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
May 30, 2026
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
May 29, 2026
AC Immune First Quarter 2026 Financial and Corporate Updates
May 27, 2026
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer’s Disease
May 27, 2026
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
May 24, 2026
1
2
Next Page
→